External beam radiation therapy (EBRT) combined with androgen deprivation are standard of care for selected patients with prostate cancer. In recent years, multiple therapies have been experimentally combined with EBRT either concomitantly or adjuvantly. These therapies include chemotherapies, immunotherapies, and novel hormones. In addition to EBRT, clinical trials with radiopharmaceuticals are planned or have been performed with concomitant chemotherapy, immunotherapies, novel hormones, and inhibitors of DNA damage repair. Herein we cover the therapeutic landscape of radiation, both EBRT and radiopharmaceuticals, and various novel therapies. Today, these therapies have yet to change the standard of care, but in the future, these combinations may improve upon currently available therapies. Clinical trials with radiation and novel forms of therapy are the key to progress, and newer adaptive clinical trial designs may allow such progress to occur faster.
Seminars in radiation oncology. 2016 Aug 26 [Epub]
Oliver Sartor, Brian Lewis
Tulane Cancer Center, Tulane Medical School, New Orleans, LA. Electronic address: ., Tulane Cancer Center, Tulane Medical School, New Orleans, LA.